![A look at the jets flying high above the Paris Air Show [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Rafale_02-scaled-e1750268097167.jpg?#)
STAT+: Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income countries gain access?
Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug, the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem.
As far as Gilead is concerned, the groundwork exists to meet that goal.
Last October, the drugmaker reached voluntary licensing agreements to eventually make lenacapavir available in 120 mostly low- and lower-middle-income countries. Then, the President’s Emergency Plan for AIDS Relief, or PEPFAR, and the Global Fund to Fight AIDS, Tuberculosis, and Malaria crafted an arrangement to cover dosing for 2 million people over three years in numerous poor countries.
